Bremelanotide: Desire and Distress Trials

The population behind the result

RECONNECT comprised two randomized, double-blind, placebo-controlled trials lasting 24 weeks. They randomized 1,267 premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD. The safety population included 1,247 women and the primary efficacy population 1,202 ^[1].

The participants had a defined diagnosis and eligibility requirements; this was not a study of sexual performance in anyone wishing to enhance it. Most participants were white and the average age was 39. Results should remain attached to that population rather than being generalized to men or all postmenopausal women ^[1].

Desire and distress were the primary outcomes

The two primary endpoints measured sexual desire and distress about low desire using specified questionnaire domains. The integrated placebo-adjusted differences were an increase of 0.35 points in desire and a reduction of 0.33 points in distress. These are changes on rating scales, not extra sexual events or percentages of participants cured ^[1].

Patient-perceived benefit provides another perspective. The prespecified anchor analysis reported responders of 58.3 percent versus 36.1 percent in one trial and 58.2 percent versus 35.4 percent in the other. The placebo response matters: quoting only the roughly 58 percent treatment figure overstates the additional response associated with medication ^[1].

The sexual-event count did not improve significantly

The prespecified count of satisfying sexual events did not show a statistically significant between-group difference. Because that endpoint failed in the testing hierarchy, the remaining ranked secondary outcomes became supportive or exploratory. Positive primary outcomes and a negative secondary count can both be true ^[1].

A later exploratory calculation examined the proportion of encounters described as satisfying rather than the number of such encounters. Changing the denominator changes the question. That result should not be substituted for the unsuccessful prespecified count, or presented as proof that treatment increased sexual activity ^[1].

Tolerability affects the practical benefit

Nausea occurred in 40.0 percent receiving bremelanotide versus 1.3 percent receiving placebo; 8.1 percent discontinued study drug because of nausea. Flushing and headache were also common. The paper reported transient blood-pressure changes, and the product’s prescribing information remains necessary for individual safety decisions ^[1].

Overall study withdrawal was higher with bremelanotide: 41.9 versus 16.0 percent in one trial and 43.8 versus 28.4 percent in the other. These are overall withdrawal figures, not all withdrawals caused by adverse events. The imbalance still matters when judging how well average questionnaire improvements represent everyone who started ^[1].

The extension was not a new placebo comparison

A 52-week open-label extension invited eligible completers from the original trials. Of 856 eligible participants, 684 entered and 272 completed the extension. Everyone received active treatment, and statistical analyses were descriptive ^[2].

The extension reported sustained symptom improvements and no new safety signals, but selection and attrition limit that finding. People who completed the core trial and elected further treatment are different from all initial participants. Without a concurrent placebo group, the extension cannot establish the same causal long-term comparison as the randomized phase ^[2].

Reading the evidence alongside the product

For a reader weighing treatment, the useful question is whether an improvement in desire and distress is meaningful enough to justify the tolerability burden in their own clinical circumstances. Neither a favorable group average nor a responder percentage promises an individual result. This evidence does not establish benefits for research material sold under the PT-141 name.

The PT-141 monograph and approved-product review explain the formulation and indication boundaries. RECONNECT answers a narrower question about measured outcomes; it is not evidence for broader performance claims or a self-treatment protocol.

Elsewhere in this index